For individuals living with long-standing psoriasis that has resisted standard therapies, the clinical landscape in 2026 offers significant new hope. The focus of modern dermatology has shifted from merely managing symptoms to achieving total skin clearance and long-term remission. In the UK, the NHS has integrated several innovative “first-in-class” medications into the standard care pathway. Furthermore, active clinical trials are exploring ways to deplete the “memory cells” in the skin that cause psoriasis to return, potentially offering a more permanent solution for those with chronic plaques.
What We’ll Discuss in This Article
- The introduction of TYK2 inhibitors as a new oral treatment option.
- The rising prominence of IL-23 inhibitors for sustained remission.
- Advanced topical foam formulations for difficult-to-treat areas.
- Ongoing UK clinical trials and registries for non-responders.
- Strategies for biologic rotation in long-standing cases.
- How to access new therapies through the NHS specialist pathway.
New oral breakthroughs: TYK2 Inhibitors
One of the most significant recent additions to the UK treatment arsenal is deucravacitinib (brand name Sotyktu). This is a “first-in-class” oral medication known as a TYK2 inhibitor.
- How it works: Unlike older oral immunosuppressants that affect the entire immune system, TYK2 inhibitors target a very specific chemical pathway involved in psoriasis inflammation.
- Clinical Eligibility: In line with NICE guidance, it is recommended for adults with moderate to severe plaque psoriasis who have not responded to, or cannot tolerate, traditional systemic treatments like methotrexate or ciclosporin.
- Benefits: It offers the convenience of a once-daily tablet with a safety profile that often requires less frequent blood monitoring than traditional systemic drugs.
The rise of IL-23 inhibitors for long remission
In 2026, the focus for long-standing cases has moved towards IL-23 inhibitors, such as risankizumab and guselkumab. These are considered “master regulators” of the psoriasis inflammatory cascade.
- Depleting Memory Cells: New research suggests that by blocking IL-23, these biologics may help deplete the “pathogenic memory T-cells” that reside in the skin and trigger flares.
- Durability: Clinical data indicates that IL-23 inhibitors provide exceptional long-term clearance. Some patients maintain clear skin for over a year even after pausing treatment, a concept known as “sustained remission.”
- Administration: These are typically given as injections every 8 to 12 weeks, making them a low-burden option for those who struggle with daily applications.
Advanced topical and foam technologies
For those with long-standing psoriasis in difficult areas, such as the scalp or thick plaques on the limbs, 2026 has seen the arrival of improved topical delivery systems.
- Ultra-Light Steroid and Vitamin D Foams: New formulations of combination foams (such as advanced versions of Enstilar) are designed to absorb rapidly without leaving a greasy residue. These are particularly effective for scalp psoriasis where traditional ointments are difficult to use.
- Precision Laser Delivery: Some specialist UK clinics now use targeted laser therapy with precision tips to reach scalp plaques through the hair, providing the benefits of phototherapy to areas previously unreachable.
Clinical trials and research registries
If your psoriasis has failed multiple lines of treatment, participating in a clinical trial or registry may be an option. The UK is a global leader in dermatology research.
- TULiPS Study (Total bUrden of Long-Term PSoriasis): This ongoing research focuses on the long-term outcomes and systemic impacts of chronic psoriasis, helping clinicians understand how to better support patients with multi-decade disease.
- BADBIR Registry: The British Association of Dermatologists Biologic and Immunomodulators Register is a massive UK study monitoring the long-term safety and effectiveness of new treatments. All patients starting biologics in the UK are encouraged to join, providing vital data for future care.
- Pipeline Trials: Trials for new JAK inhibitors and novel oral molecules (like zasocitinib) are actively recruiting in the UK, often focusing on patients who have not achieved results with current biologics.
Biologic rotation strategies
In 2026, dermatologists are increasingly using “rotation strategies” for patients with long-standing disease. If a biologic stops working after several years (secondary failure), clinicians now have enough different “classes” of biologics to switch to a different pathway. For example, a patient might move from a TNF-alpha inhibitor to an IL-17 or IL-23 inhibitor. This tailored approach ensures that even “resistant” cases can find a medication that effectively clears their skin.
Conclusion
The options for long-standing psoriasis in the UK have never been more advanced. From the arrival of highly targeted oral tablets like deucravacitinib to the potential for long-term remission with IL-23 inhibitors, the goal of treatment has moved beyond simple management. If you have lived with psoriasis for many years and feel your current treatment is insufficient, a referral to a specialist psoriasis clinic is essential. These specialist centres provide access to the latest NICE-approved biologics and the opportunity to participate in groundbreaking clinical research.
How do I find out about active clinical trials?
You can search the NIHR (National Institute for Health and Care Research) “Be Part of Research” website or ask your consultant dermatologist if their hospital is currently running any trials.
Is deucravacitinib better than a biologic injection?
While biologics often achieve slightly higher rates of total skin clearance, deucravacitinib is a highly effective oral alternative for those who prefer not to inject or have certain contraindications to biologics.
What is a “biosimilar” biologic?
A biosimilar is a highly similar, more cost-effective version of an original biologic medication. The NHS uses these to free up resources, allowing more patients to access advanced therapies.
Can new treatments prevent psoriatic arthritis?
Recent studies, such as the PAMPA trial, are investigating whether starting IL-23 inhibitors early can actually prevent the progression to psoriatic arthritis in people with skin psoriasis.
Will I have to pay to join a clinical trial?
No; participants in clinical trials in the UK do not pay for the medication or the extra monitoring. In many cases, travel expenses are also reimbursed.
Why does my dermatologist want me to try methotrexate first?
NHS protocols usually require patients to try “traditional” systemic treatments before moving to more expensive biologics or TYK2 inhibitors.
Is there a new treatment for nail psoriasis?
Many of the newer biologics, particularly IL-17 and IL-23 inhibitors, have shown excellent results in clearing stubborn nail psoriasis that was previously very difficult to treat.
Authority Snapshot (E-E-A-T Block)
This article examines the latest clinical advancements and research opportunities for long-standing psoriasis in 2026. It is written by the MyPatientAdvice Medical Writing/Research Team and reviewed by Dr. Rebecca Fernandez, a UK-trained physician with experience in dermatology and clinical research. All information is strictly aligned with the latest NICE appraisals and NHS treatment pathways for 2026.
